Autism and Obsessive Compulsive Spectrum Program

Publictions

  1. Fineberg, N. A., Demetrovics, Z., Stein, D. J., Ioannidis, K., Potenza, M. N., Grünblatt, E., ...Hollander, E., … & Grant, J. E. (2018). Manifesto for a European research network into Problematic Usage of the Internet. European Neuropsychopharmacology, 28(11), 1232-1246. 
  2. Del Valle Rubido, M., McCracken, J. T., Hollander, E., Shic, F., Noeldeke, J., Boak, L., ... & Umbricht, D. (2018). In Search of Biomarkers for Autism Spectrum Disorder. Autism Research, 11(11), 1567-1579.
  3. Hollander, E., Uzunova, G., Taylor, B. P., Noone, R., Racine, E., Doernberg, E.,... & Ferretti, C. J. (2018). Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder. The World Journal of Biological Psychiatry, 1-9.
  4. Burchi, E., Hollander, E., & Pallanti, S. (2018). From treatment response to recovery: a realistic goal in OCD. International Journal of Neuropsychopharmacology, 21(11), 1007-1013.
  5. Hong, K., Nezgovorova, V., Uzunova, G., Schlussel, D., & Hollander, E. (2018). Pharmacological Treatment Of Body Dysmorphic Disorder. Current neuropharmacology.
  6. Mitelman, S. A., Buchsbaum, M. S., Young, D. S., Haznedar, M. M., Hollander, E., Shihabuddin, L., ... & Bralet, M. C. (2018). Increased white matter metabolic rates in autism spectrum disorder and schizophrenia. Brain imaging and behavior, 12(5), 1290-1305.
  7. Dell’Osso, B., Benatti, B., Arici, C., Palazzo, C., Altamura, A. C., Hollander, E., ... & Marazziti, D. (2018). Prevalence of suicide attempt and clinical characteristics of suicide attempters with obsessive-compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). CNS spectrums, 23(1), 59-66.Sdsf
  8. Mitelman, S. A., Bralet, M. C., Haznedar, M. M., Hollander, E., Shihabuddin, L., Hazlett, E. A., & Buchsbaum, M. S. (2018). Positron emission tomography assessment of cerebral glucose metabolic rates in autism spectrum disorder and schizophrenia. Brain imaging and behavior, 12(2), 532-546.
  9. Kabasakalian A., Ferretti C.J., Hollander E. (2017) Oxytocin and Prader-Willi Syndrome. In: Hurlemann R., Grinevich V. (eds) Behavioral Pharmacology of Neuropeptides: Oxytocin. Current Topics in Behavioral Neurosciences, vol 35. Springer, Cham
  10. Dell'Osso, B., Benatti, B., Rodriguez, C.I., Arici, C., Palazzo, C., Altamura, A.C., Hollander, E., … & Zohar. J. (2017) Obsessive-compulsive disorder in the elderly: A report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). European Psychiatry, 45, 36 – 40.
  11. Umbricht, D., del Valle Rubido, M., Hollander, E., McCracken, J. T., Shic, F., Scahill, L., ... & Grundschober, C. (2017). A single dose, randomized, controlled proof-of-mechanism study of a novel vasopressin 1a receptor antagonist (RG7713) in high-functioning adults with autism spectrum disorder. Neuropsychopharmacology, 42(9), 1914.
  12. Chiarello, F., Spitoni, S., Hollander, E., Matucci Cerinic, M., & Pallanti, S. (2017). An expert opinion on PANDAS/PANS: highlights and controversies. International journal of psychiatry in clinical practice, 21(2), 91-98.B
  13. Vasudeva, S. B., & Hollander, E. (2017). Body Dysmorphic Disorder in Patients With Autism Spectrum Disorder: A Reflection of Increased Local Processing and Self-Focus. American Journal of Psychiatry, 174(4), 313-316.
  14. Hollander, E., & Uzunova, G. (2017). Are there new advances in the pharmacotherapy of autism spectrum disorders?. World Psychiatry, 16(1), 101-102.
  15. Mitelman, S. A., Bralet, M. C., Haznedar, M. M., Hollander, E., Shihabuddin, L., Hazlett, E. A., & Buchsbaum, M. S. (2017). Diametrical relationship between gray and white matter volumes in autism spectrum disorder and schizophrenia. Brain imaging and behavior, 11(6), 1823-1835.
  16. Dell’Osso, B., Benatti, B., Hollander, E., & Altamura, A. C. (2017). Clinical features associated with increased severity of illness in tertiary clinic referred patients with obsessive compulsive disorder. International journal of psychiatry in clinical practice, 21(2), 131-136.
  17. Dell'Osso, B., Benatti, B., Altamura, A. C., & Hollander, E. (2016). Prevalence of Selective Serotonin Reuptake Inhibitor–Related Apathy in Patients With Obsessive Compulsive Disorder. Journal of clinical psychopharmacology, 36(6), 725-726.
  18. Palkar P, Kabasakalian A, Taylor B, Doernberg E, Ferretti C, Uzunova G, Hollander E. Behavioral phenotype in a child with Prader-Willi syndrome and comorbid 47, XYY. Intractable Rare Dis Res. 2016 Aug; 5(3): 235–237.
  19. King BH…Hollander E et al. Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial. JAMA Pediatr. 2013 Nov;167(11):1045-52
  20. Hallett V, Lecavalier L, Sukhodolsky DG, Cipriano N, Aman MG, McCraken JT, McDougle CJ, Tierney E, King BH, Hollander E et al. Exploring the Manifestations of Anxiety in Children with Autism Spectrum Disorders. J Autism Dev Disord 2013 Feb 12 [Epub ahead of print].
  21. Anagnostou E, Soorya L, Chaplin W, Bartz J, Halpern D, Wasserman S, Wang AT, Pepa L, Tanel N, Kushki A, Hollander E. Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Molecular Autism, 2012. 3(1): p. 16.
  22. Girgis RR, Slifstein M, Xu X, Frankle WG, Anagnostou E, Wasserman S, Pepa L, Kolevzon A, Abi-Dargham A, Laruelle M, Hollander E. The 5-HT (2A) receptor and serotonin transporter in Asperger’s disorder: A PET study with [11C]MDL 100907 and [11C]DASB. Psychiatry Res. 194(3):230-4. 2011
  23. Hollander E, Soorya L, Chaplin W, Anagnostou E, Taylor BP, Ferretti CJ, Wasserman S, Swanson E, Settipani C. A Double-Blind Placebo-Controlled Trial of Fluoxetine for Repetitive Behaviors and global Severity in Adult Autism Spectrum Disorders. Am J Psychiatry. 2011 Dec 2 [Epub ahead of print].
  24. Bartz JA, Zaki J, Bolger N, Hollander E, Ludwig NN, et al. Oxytocin selectively improves empathic accuracy. Psychol Sci. 21(1):1426-8, 2010.
  25. Green JJ, Hollander E. Autism and oxytocin: new developments in translational approaches to therapeutics. Neurotherapeutics 7(3):250-7, 2010.
  26. Hollander E, Chaplin W, Sorrya L, Wasserman S, Novotny S, et al. Divalproex sodium vs. placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology 35(4): 990-8. 2010. Epub 2009 Dec 9.
  27. Hollander E, Bartz J, Chaplin W, Phillips A, Sumner J, et al. Oxytocin increases retention of social cognition in autism. Biol Psychiatry 15;61(4):498-503, 2007. Epub 2006 Aug 10.
  28. Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 30:582-9, 2005.
  29. Hollander E, Anagnostou E, Chaplin W, Esposito K, Haznedar MM, et al. Striatal volume on magnetic resonance imaging and repetitive behaviors in autism. Biol Psychiatry 58(3):226-32, 2005.
  30. Hollander E, Novotny S, Hanratty M, Yaffe R, DeCaria CM, Aronowitz BR, Mosovich S. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger’s disorders. Neuropsychopharmacology 28(1):193-8, 2003.